www.infystocks.co.uk

26 October 2007

RECOMEDATION

Growth story OF DIVIS LAB

ON request of mr. pv sharma (new delhi) we are giving infomation about Divis

Established in the year 1990, with Research & Development as its prime fundamental, Divis Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.

With five years of experience, expertise and a proven track-record of helping many companies with its turn-key and consulting strengths, Divis Laboratories established its first manufacturing facility in 1995.

Built on a 300 acre site at Hyderabad (Unit-I). the plant comprises of 13 multi-purpose production blocks and has space for further growth and expansion.

Divis Laboratories set up its second manufacturing facility at Visakhapatnam (Unit-II). in the year 2002 on a314 acre site. The site has 7 multi purpose production blocks.

Both the facilities are primarily engaged in the manufacture of:
Active Pharmaceutical Ingredients (APIs) & Intermediates for Generics
Custom Synthesis of API's and Advanced intermediates for discovery compounds for
pharma giants
Building blocks for Peptides
Building blocks for Nucleotides
Carotenoids
Chiral ligands

Complete cGMP guidelines are complied to in both the plants. The Unit-1 at Hyderabad was successfully inspected by the US FDA during September 2000 and again in April 2004. The Unit-2 at Visakhapatnam was successfully inspected by the US FDA during November 2006. Divis also undertakes FTE/Contract Research on process development for discovering new compounds for leading MNCs across the world and partners with them for the supply of APIs. The company is global in its outlook and benchmarks its quality standards to the best in the world.




Divis Labs
1646.75 178.15 (12.13%)

(BSE: 532488 | NSE: DIVISLAB | ISIN: INE361B01024)

* BSE
* NSE
* Oct 26, 16:00


Current Price 1646.75
Change 178.15
High 1662.00
Low 1471.00
Volume 178061
52 week High 1662.00
52 week Low 346.00



* BSE
* NSE
* Oct 26, 15:59

Compare with peers
Current Price 1645.40
Change 182.7
High 1660.00
Low 1470.00
Volume 665560
52 week High 1657.00
52 week Low 346.43

Hold it for long term. immediate target Rs. 2000

And see the result in 3 days
stock to buy

1 Sesagoa sl 3000 . resistance 3567 if breaches , 3786 in few minutes
2 . Orbit corpoation cmp576 trag 723 stop loss 545 if breaches 621 see flying movements
3 Divis Lab above 1500 can zoom to 1689 stop loss 1432
4. Sterlite above 900 will kiss 1155 soon sl888
5. Dhanus tec buy above 345 sl 320 trag 456

6. Teledata CMP 68 TRAG 89 SL 66
7. DLF cmp 868 sl 850 tag 956
8. Hcl tec CMP 300 TARHG 389 SL 288 ( IF BREACHES STOP LOSS EVEN THAN WE CAN HOLD IT) ALONG WITH NIFTY TRAGET 5710

GO FOR RELIGARE IPO WILL GET 80% RETURN ON SAME DAY

Religare Enterprises is a holding company of 11 subsidiaries, which are engaged in a wide range of financial products and services targeted at the retail, high net worth individuals and the corporate and institutional clients. Along with its various subsidiaries, it offers a wide range of services ranging from equities, commodities, insurance broking, to wealth advisory, portfolio management services, personal finance services, investment banking and institutional broking services.

REL’s consolidated total income increased from Rs 311.27 million in fiscal 2006 to Rs 3,201.18 million in fiscal 2007. Its net profit increased from Rs 106.20 million in fiscal 2006 to Rs 250.21 million in fiscal 2007. It posted a consolidated Total Income of Rs 3,079.64 million and a net profit of Rs 367.26 million during the first half of fiscal 2008.

you can ask one stock inquiry welcome we will post on web mails us on usasparrow@yahoo.com

by erectusplus at 15:49:00 |